This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kazia Therapeutics Future Growth

Future criteria checks 3/6

Kazia Therapeutics is forecast to grow earnings and revenue by 49.6% and 47.7% per annum respectively. EPS is expected to grow by 59.7% per annum. Return on equity is forecast to be 25% in 3 years.

Key information

49.6%

Earnings growth rate

59.7%

EPS growth rate

Biotechs earnings growth	14.9%
Revenue growth rate	47.7%
Future return on equity	25.0%
Analyst coverage	Low
Last updated	10 Aug 2023

Recent future growth updates

Recent updates

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Jun 24

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Feb 24

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

Nov 03

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Sep 23

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

May 04

When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?

Mar 27

Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

Feb 28

What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?

Feb 01

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Jan 06

Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts

Dec 11

Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?

Nov 26

Earnings and Revenue Growth Forecasts

ASX:KZA - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	3	-17	N/A	N/A	1
6/30/2025	11	-6	7	7	2
6/30/2024	11	-7	7	7	2
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	-6	-6	N/A
6/30/2019	1	-10	-7	-7	N/A
3/31/2019	2	-11	-6	-6	N/A
12/31/2018	2	-12	-5	-5	N/A
9/30/2018	3	-9	-7	-7	N/A
6/30/2018	3	-6	-9	-9	N/A
3/31/2018	4	-6	-10	-10	N/A
12/31/2017	6	-6	-12	-12	N/A
9/30/2017	7	-8	-12	-12	N/A
6/30/2017	9	-11	-11	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A
6/30/2015	2	-7	N/A	-6	N/A
3/31/2015	2	-7	N/A	-5	N/A
12/31/2014	2	-7	N/A	-5	N/A
9/30/2014	1	-7	N/A	-5	N/A
6/30/2014	0	-7	N/A	-6	N/A
3/31/2014	0	-6	N/A	-5	N/A
12/31/2013	1	-5	N/A	-3	N/A
9/30/2013	1	-3	N/A	-6	N/A
6/30/2013	1	-2	N/A	-9	N/A
3/31/2013	1	-1	N/A	-11	N/A
12/31/2012	1	1	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KZA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KZA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KZA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KZA's revenue (47.7% per year) is forecast to grow faster than the Australian market (4% per year).

High Growth Revenue: KZA's revenue (47.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KZA's Return on Equity is forecast to be high in 3 years time (25%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/11/15 14:05
End of Day Share Price	2023/11/13 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kazia Therapeutics Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Soo Romanoff	Edison Investment Research
Nazibur Rahman	Maxim Group

This company listing is no longer active

Kazia Therapeutics Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Forecast to breakeven in 2024

Price target decreased to AU$0.45

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Consensus forecasts updated

Recent updates

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

New major risk - Market cap size

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Forecast to breakeven in 2024

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

Price target decreased to AU$0.45

No longer forecast to breakeven

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

No longer forecast to breakeven

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

No longer forecast to breakeven

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Consensus forecasts updated

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Insufficient new directors

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Consensus forecasts updated

Consensus forecasts updated

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Price target decreased to AU$1.90

Independent Non-Executive Director recently bought AU$54k worth of stock

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

No longer forecast to breakeven

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.072 loss per share (vs AU$0.17 loss in FY 2020)

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Consensus forecasts updated

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Consensus forecasts updated